[Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy; D006951:Hyperlipoproteinemias / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014652:Vascular Diseases / Q000150:complications
D006025:Glycosaminoglycans; D000960:Hypolipidemic Agents; D010919:Placebos; C007858:glucuronyl glucosamine glycan sulfate
Valutazione di un sulfomucopolisaccaride (3GS) nel trattamento delle iperlipoproteinemie.